Background Bleomycin (BLM) is an anticancer antibiotic used in many cancer regimens. Its utility is limited by systemic toxicity and dose-dependent pneumonitis able to progress to lung fibrosis. The latter can affect up to nearly 50% of the total patient population, out of which 3% will die. We propose to improve BLM delivery by tethering it to an efficient delivery vector. Adenovirus (Ad) dodecahedron base (DB) is a particulate vector composed of 12 copies of a pentameric viral protein responsible for virus penetration. The vector efficiently penetrates the plasma membrane, is liberated in the cytoplasm and has a propensity to concentrate around the nucleus; up to 300000 particles can be observed in one cell in vitro. Principal Findings Dodecahedron (Dd) structure is preserved at up to about 50°C at pH 7–8 and during dialysis, freezing and drying in the speed-vac in the presence of 150 mM ammonium sulfate, as well as during lyophilization in the presence of cryoprotectants. The vector is also stable in human serum for 2 h at 37°C. We prepared a Dd-BLM conjugate which upon penetration induced death of transformed cells. Similarly to free bleomycin, Dd-BLM caused dsDNA breaks. Significantly, effective cytotoxic concentration of BLM delivered with Dd was 100 times lower than that of free bleomycin. Conclusions/Significance Stability studies show that Dds can be conveniently stored and transported, and can potentially be used for therapeutic purposes under various climates. Successful BLM delivery by Ad Dds demonstrates that the use of virus like particle (VLP) results in significantly improved drug bioavailability. These experiments open new vistas for delivery of non-permeant labile drugs.
References
[1]
Norrby E (1968) Comparison of soluble components of adenovirus types 3 and 11. J Gen Virol 2: 135–142.
[2]
Fender P, Ruigrok RW, Gout E, Buffet S, Chroboczek J (1997) Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol 15: 52–56.
[3]
Vives RR, Lortat-Jacob H, Chroboczek J, Fender P (2004) Heparan sulfate proteoglycan mediates the selective attachment and internalization of serotype 3 human adenovirus dodecahedron. Virology 321: 332–340.
[4]
Garcel A, Gout E, Timmins J, Chroboczek J, Fender P (2006) Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors. J Gene Med 8: 524–531.
[5]
Noad R, Roy P (2003) Virus-like particles as immunogens. Trends Microbiol 11: 438–444.
[6]
Rexroad J, Evans RK, Middaugh CR (2006) Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci 95: 237–247.
[7]
Zubieta C, Schoehn G, Chroboczek J, Cusack S (2005) The structure of the human adenovirus 2 penton. Mol Cell 17: 121–135.
[8]
Ishizu KI, Watanabe H, Han SI, Kanesashi SN, Hoque M, et al. (2001) Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein. J Virol 75: 61–72.
[9]
Chen PL, Wang M, Ou WC, Lii CK, Chen LS, et al. (2001) Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett 500: 109–113.
[10]
McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA (1998) Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 72: 32–41.
[11]
Takeshita M, Grollman AP, Ohtsubo E, Ohtsubo H (1978) Interaction of bleomycin with DNA. Proc Natl Acad Sci U S A 75: 5983–5987.
[12]
Poddevin B, Orlowski S, Belehradek J Jr, Mir LM (1991) Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 42: SupplS67–75.
[13]
Hecht SM (1994) RNA degradation by bleomycin, a naturally occurring bioconjugate. Bioconjug Chem 5: 513–526.
[14]
Mir LM, Tounekti O, Orlowski S (1996) Bleomycin: revival of an old drug. Gen Pharmacol 27: 745–748.
[15]
Sebti SM, Lazo JS (1988) Metabolic inactivation of bleomycin analogs by bleomycin hydrolase. Pharmacol Ther 38: 321–329.
[16]
Chen J, Stubbe J (2005) Bleomycins: towards better therapeutics. Nat Rev Cancer 5: 102–112.
[17]
Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678–5694.
[18]
Fender P, Boussaid A, Mezin P, Chroboczek J (2005) Synthesis, cellular localization, and quantification of penton-dodecahedron in serotype 3 adenovirus-infected cells. Virology 340: 167–173.
[19]
Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, et al. (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166: 5346–5355.
[20]
Jiang X, Wang M, Graham DY, Estes MK (1992) Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 66: 6527–6532.
[21]
Fabry CM, Rosa-Calatrava M, Conway JF, Zubieta C, Cusack S, et al. (2005) A quasi-atomic model of human adenovirus type 5 capsid. Embo J 24: 1645–1654.
[22]
Balakireva L, Schoehn G, Thouvenin E, Chroboczek J (2003) Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry. J Virol 77: 4858–4866.
[23]
Fender P, Schoehn G, Perron-Sierra F, Tucker GC, Lortat-Jacob H (2008) Adenovirus dodecahedron cell attachment and entry are mediated by heparan sulfate and integrins and vary along the cell cycle. Virology 371: 155–164.
[24]
Li TC, Takeda N, Kato K, Nilsson J, Xing L, et al. (2003) Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses. Virology 311: 115–124.
[25]
Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 3: e2257.
[26]
Shi L, Sanyal G, Ni A, Luo Z, Doshna S, et al. (2005) Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94: 1538–1551.
[27]
Brady JN, Winston VD, Consigli RA (1977) Dissociation of polyoma virus by the chelation of calcium ions found associated with purified virions. J Virol 23: 717–724.
[28]
Lehane DE, Hurd E, Lane M (1975) The effects of bleomycin on immunocompetence in man. Cancer Res 35: 2724–2728.
[29]
Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, et al. (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57: 45–56.
[30]
Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS (1991) Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res 51: 227–232.
[31]
Hecht SM (2000) Bleomycin: new perspectives on the mechanism of action. J Nat Prod 63: 158–168.
[32]
Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120: 617–624.
[33]
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309–319.
[34]
Eliceiri BP, Cheresh DA (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103: 1227–1230.
[35]
Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15: 542–546.
[36]
Yanai H, Kubota Y, Nakada T (2002) Effects of electropermeabilization after the administration of anticancer drugs on transitional cell carcinoma. BJU Int 89: 438–442.
[37]
Horiuchi A, Nikaido T, Mitsushita J, Toki T, Konishi I, et al. (2000) Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer 88: 640–644.
[38]
Wang C, Liu J, Pan W, Wang X, Gao Q, et al. (2008) Pingyangmycin loaded bovine serum albumin microspheres for chemoembolization therapy–in vitro and in vivo studies. Int J Pharm 351: 219–226.
[39]
Sonoda S, Tachibana K, Uchino E, Yamashita T, Sakoda K, et al. (2007) Inhibition of melanoma by ultrasound-microbubble-aided drug delivery suggests membrane permeabilization. Cancer Biol Ther 6: 1276–1283.
[40]
Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 50: 6371–6378.
[41]
Arndt D, Zeisig R, Bechtel D, Fichtner I (2001) Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv 8: 1–7.
[42]
Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ (1994) Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 54: 4933–4939.
[43]
Demarcq C, Bunch RT, Creswell D, Eastman A (1994) The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5: 983–993.
[44]
Lock RB, Stribinskiene L (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006–4012.
[45]
Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, et al. (2008) Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32: 1031–1043.
[46]
Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, et al. (2008) Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech Ageing Dev.
[47]
Berg K, Dietze A, Kaalhus O, Hogset A (2005) Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res 11: 8476–8485.
[48]
Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, et al. (2008) Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34: 232–240.
[49]
Larkin JO, Casey GD, Tangney M, Cashman J, Collins CG, et al. (2008) Effective tumor treatment using optimized ultrasound-mediated delivery of bleomycin. Ultrasound Med Biol 34: 406–413.
[50]
Cobbold SP, Adams E, Graca L, Daley S, Yates S, et al. (2006) Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 213: 239–255.
[51]
Gallegos CO, Patton JT (1989) Characterization of rotavirus replication intermediates: a model for the assembly of single-shelled particles. Virology 172: 616–627.
[52]
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.
